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Abstract
The growth of metastatic tumors in mice can result in markedly increased lymph flow through tumor-draining
lymph nodes (LNs), which is associated with LN lymphangiogenesis. A dynamic magnetic resonance imaging
(MRI) assay was developed, which uses low–molecular weight gadolinium contrast agent to label the lymphatic
drainage, to visualize and quantify tumor-draining lymph flow in vivo in mice bearing metastatic melanomas.
Tumor-bearing mice showed greatly increased lymph flow into and through draining LNs and into the bloodstream.
Quantitative analysis established that both the amount and the rate of lymph flow through draining LNs are sig-
nificantly increased in melanoma-bearing mice. In addition, the rate of appearance of contrast media in the blood-
stream was significantly increased in mice bearing melanomas. These results indicate that gadolinium-based
contrast-enhanced MRI provides a noninvasive assay for high-resolution spatial identification and mapping of lym-
phatic drainage and for dynamic measurement of changes in lymph flow associated with cancer or lymphatic dys-
function in mice. Low–molecular weight gadolinium contrast is already used for 1.5-T MRI scanning in humans,
which should facilitate translation of this imaging assay.
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Introduction
The lymphatic system transports fluid and cells from the periphery to
the circulation. This system is increasingly appreciated as a conduit
for metastasis of a variety of human cancers including breast, colon,
melanoma, and head and neck cancers (reviewed by Achen et al. [1]
and Cao [2]). Tumor lymphatic vessel growth or lymphangiogenesis
is often associated with metastasis and poor prognosis [3]. More-
over, studies of murine models have shown that vascular endothelial
growth factor–induced lymphangiogenesis promotes tumor metasta-
sis to lymph nodes (LNs) [4,5]. Thus, investigation of the lymphatic
contribution to metastasis may to lead to diagnostic or therapeutic
strategies to identify or prevent tumor dissemination.
Tumor metastasis is commonly diagnosed by examination of sen-
tinel or tumor-draining lymph nodes (TDLNs) for the presence of
tumor cells. However, an active involvement of the sentinel LN in
tumor dissemination was not considered until the discovery that
TDLNs can undergo extensive lymphangiogenesis [6,7]. This lym-
phatic sinus growth is associated with greatly increased lymph flow,
detected by optical imaging of fluorescent nanoparticle or quantum
dot accumulation within TDLNs in mice bearing B16-F10 melano-
mas [8] and in LNs from Eμ-c-myc transgenic mice developing B-cell
lymphoma [7]. B-cell accumulation within the TDLN is required
for LN lymphangiogenesis and for increased lymph flow [8]. More-
over, B-cell–deficient mice show reduced melanoma metastasis to
LNs, supporting the idea that increased lymph flow through LNs
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promotes tumor dissemination. Tumor vascular endothelial growth
factor C overexpression can also stimulate lymph drainage from fi-
brosarcomas in part by increasing the number and size of tumor lym-
phatic vessels [9]. Such findings indicate dynamic alterations of
lymph drainage in response to tumor growth, which could actively
promote metastasis.
We sought to develop a more sensitive assay to analyze lymph
drainage throughout the mouse, to further characterize tumor effects
on lymph flow. Near infrared optical imaging shows promise for im-
aging superficial mouse lymph drainage; however, optical imaging is
relatively low in resolution, and it does not detect deep lymphatic
drainage basins [10,11]. Magnetic resonance imaging (MRI) provides
superior three-dimensional (3D) resolution of surface or deep struc-
tures, and the lymphatic drainage can be labeled after injection of
gadolinium contrast [12]. Therefore, we pursued an MRI strategy
for murine lymphography (or lymphangiography). For lymphogra-
phy, particles of 5 to 50 nm in diameter are generally used, because
larger molecules are selectively taken up by and retained within lym-
phatic vessels [13]. A variety of experimental nanoparticles and
dendrimers with these dimensions are being synthesized and tested
for lymphography [14,15]. However, some gadolinium-based low–
molecular weight contrasts such as dimeglumine gadopentate (Gd-
DTPA) have been successfully used to identify lymphatic vessels
and LNs in humans [16,17] and in dogs [18]. In addition, a re-
cent report successfully used Gd-DTPA to image lymphatic vessels
in the mouse tail [19], suggesting that low–molecular weight contrast
agents may be useful for lymphography in mice.
In this study, we developed methods using low–molecular weight
gadolinium contrast for high-resolution spatial mapping of lymph
drainage in mice and for dynamic monitoring of lymph flow. We
used the B16-F10 melanoma model for these studies, because we
had found previously that implantation of B16-F10 cells into the rear
footpad of syngeneic C57Bl/6 mice reliably increases lymph flow
through the draining popliteal LN [8]. We determined that low–
molecular weight Gd-DTPA makes an excellent MRI contrast for
mouse lymphography, which allowed us to demonstrate significantly
increased lymph flow into the tumor-draining lymphatic basin and
then into the vascular circulation. Magnetic resonance imaging lym-
phography using low–molecular weight gadolinium contrast provides
a useful tool for the localization and functional assessment of diseased
or tumor-draining lymphatic vessels and LNs.
Methods
Mouse Tumor Model
Four-week-old C57BL/6J wild type mice were obtained from
Jackson Laboratories (Bar Harbor, ME) and maintained in micro-
isolator rooms at the Fred Hutchinson Cancer Research Center
(FHCRC) animal facility under specific pathogen-free conditions.
Experimental mice were injected in the left hind leg footpad with
200,000 B16-F10 cells (American Type Culture Collection, Manassas,
VA) in 50 μl of Hanks’ buffered saline solution (Gibco Life Technol-
ogies, Grand Island, NY), after testing to confirm that the cells were
free of mycoplasma contamination (Cambrex, Rockland, MD). Mice
were imaged at 20 to 23 days when tumors were 2 to 4 mm in di-
ameter and were then killed by cervical dislocation. Experiments in-
volving animals were approved by the FHCRC and University of
Washington Animal Care and Use Committees.
Magnetic Resonance Image Acquisition
Mice were anesthetized with 2% to 3% isoflurane through an
MR-compatible mobile inhalation system (DRE, Inc, Louisville,
KY) and were positioned supine in a coil with 2% isoflurane main-
tenance. Coronal MR images were acquired on a 1.5-T clinical MRI
system (Signa whole-body MRI scanner; General Electric Medical
Systems, Milwaukee, WI) using a 2.5-cm-diameter solenoidal radio-
frequency coil (built in-house) and a customized animal holder sur-
rounded by 37°C heating pads (Braintree Scientific, Braintree, MA).
For lymphography, the dorsal toe of the rear foot was injected sub-
cutaneously with 25 μl of Gd-DTPA (0.4 mM/kg Magnevist; Bayer
Pharmaceuticals, Wayne, NJ). For angiography, 25 μl of Gd-DTPA
was injected into the lateral tail vein. Contrast-enhanced imaging
was performed using a coronal T1-weighted 3D fast gradient echo
sequence [20]. The scanning protocol consisted of a high spatial
resolution acquisition followed by two dynamic acquisitions before
contrast injection and 10 postcontrast dynamic (high temporal reso-
lution) 1-minute scans, followed by a final high spatial resolution
acquisition. The high spatial resolution sequence was obtained using
T R = 15.5 milliseconds, T E = 6.3 milliseconds, flip angle = 45°, field
of view = 6 × 3 cm, imaging matrix = 256 × 160, slice thickness =
0.6 mm, number of excitations = 3, with approximately 42 slices for
an acquisition time of 5 minutes 13 seconds. This sequence provided
an in-plane image resolution of 0.2 mm. The dynamic sequence was
obtained using T R = 15.1 milliseconds, T E = 6.3 milliseconds, flip
angle = 45°, field of view = 6 × 3 cm, imaging matrix = 256 × 128,
slice thickness = 0.8 mm, number of excitations = 1, with approxi-
mately 30 slices for an acquisition time of 59 seconds.
Image Analysis
Image analysis was performed using ImageJ software (National In-
stitutes of Health, Bethesda, MD), with automation using Java-based
software developed in-house. Regions of interest (ROIs) were cal-
culated from T1-weighted 3D images by manually delineating ROIs
on sequential MR images over one or more slices, and summing
the volumes. For popliteal LN quantitation, the ROI was determined
by inspection of precontrast slices to identify the popliteal fossa.
Tumor-draining popliteal LNs were typically four times larger than
normal [8], so that the ROI drawn was twice as large, and the num-
ber of slices measured was doubled from three to six slices for these
LNs. Inguinal LNs were identified from postcontrast volumes. The
same-size ROI was used over four slices for the similarly sized tumor-
draining and control inguinal LNs. The integrated density (sum of
the pixel values in selected postcontrast ROIs minus the sum of pixel
values in precontrast ROIs) was then measured for each LN.
The central lymphatic vessel, right iliac blood vessels, and heart
were quantified by drawing ROIs within each structure on a repre-
sentative single slice at each time point, for pixel value measurement.
The percent enhancement was calculated as the sum of the post-
injection ROI pixel values minus the precontrast pixel values, divided
by the precontrast values, multiplied by 100. Seven to nine tumor-
bearing or control mice were analyzed in each group, and statis-
tics were analyzed by 2-tailed Student’s t-test. Blinded samples were
independently evaluated by two observers, which yielded compara-
ble results.
Volocity software (Improvisation Inc, Waltham, MA) was used to
construct 3D time-course movies. A 3D image of each slice stack was
created using dynamic scans taken from 1 to 10 minutes after con-
trast injection, and the images were aligned sequentially over time.
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Movies were converted to avi file format to permit Windows or Mac
platform viewing.
Results
High-Resolution MRI Lymphography
Low–molecular weight gadolinium contrast was tested for high
spatial resolution analysis of normal lymph drainage from the mouse
hind leg. We previously characterized the lymph drainage of the
mouse hind leg using Evans Blue dye injection [10]. The major lym-
phatic vessels drain into the popliteal or inguinal LNs, and then into
the iliac plexus, iliac LNs, and other LNs traveling up the midline,
before delivery into the subclavian vein and blood circulation [21], as
illustrated in Figure 1A. Gd-DTPA contrast (Magnevist) was injected
into the dorsal toe of the hind leg of anesthetized normal mice, fol-
lowed by high-resolution image collection on a 1.5-T Signa clinical
MRI scanner.
High-resolution maximum intensity projection (MIP) images of a
normal mouse 25 to 30 minutes after contrast injection into the
dorsal toe (Figure 1B, arrow) reveal labeling of the major leg lym-
phatic vessels entering the popliteal or inguinal LNs (Figure 1B,
arrowheads). Contrast continued traveling through the iliac plexus
and then up the midline through the iliac, renal, and para-aortic
LNs toward the heart (Figure 1B, “H”). The contrast-enhanced ves-
sel abruptly terminated at the heart, presumably because the con-
trast was greatly diluted as it entered the blood circulation. These
contrast-enhanced vessels and LNs were readily distinguished from
background, shown in a precontrast image (Figure 1C ). Thus, the
Figure 1. High-resolution MRI lymphography demonstrates tumor-induced lymph drainage. (A) Map of hind foot lymph drainage through
major lymphatic vessels (gray) and LNs (black circles). IL indicates iliac LN; IN, inguinal LN; IP, iliac plexus; PO, popliteal LN; RE, renal
LN. (B) High-resolution MIP of the control mouse 30 minutes after injection of Gd-DTPA into the dorsal toe (arrow) of the hind leg labels
popliteal and inguinal nodes (arrowheads), central lymphatic vessel and LNs (dashed line), and lymph drainage into the heart (“H”) in a
normal mouse. (C) High-resolution precontrast MIP of mouse before Gd-DTPA injection. (D) High-resolution MIP of tumor-bearing
mouse 30 minutes after injection of Gd-DTPA into the dorsal toe (arrow) of the tumor-draining foot (asterisk). Popliteal and inguinal
LNs are labeled (arrowheads), and the contrast has reached the heart and traveled through to the vascular circulation on the contralateral
side (“V”). The wide vena cava and aorta are labeled (solid lines) as well as the thin central lymphatic vessel (dashed line). (E) Toes on
both legs of a mouse bearing a tumor in the left hind foot (asterisk) were injected simultaneously (arrows), highlighting the lymphatic
vessels on both sides of the animal at 7 minutes after contrast injection. Lymph drainage is greatly increased from the tumor-bearing
leg. Note that two thin central lymphatic vessels are labeled when both hind legs are injected with contrast (arrowheads). (F) Imaging at
6 minutes after intravenous tail vein injection identifies blood vessels of tumor-bearing mouse.
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Gd-DTPA contrast appeared to label major afferent and efferent
lymphatic vessels and LNs draining the foot, and extending all the
way up the midline to empty into the bloodstream. Moreover, the
lymphatic vessels and LNs identified by contrast-enhanced MRI lym-
phography match those identified by Evans Blue dye injection [10].
Tumor-Induced Lymph Flow
B16-F10 melanomas grown in the rear footpad increase lymph
drainage through the popliteal LN at early stages within 3 weeks after
implantation, despite the small size of these tumors [8]. Gadolinium
contrast-enhanced MRI was performed after dorsal toe injection to
characterize this tumor-induced lymph flow. The pattern of lymph
labeling in these mice (Figure 1D) was very different from that ob-
served in control mice at 30 minutes after the injection of contrast
(Figure 1B). In addition to strong labeling of the tumor-draining
lymphatic vessels and LNs, Gd-DTPA labeled the heart and blood
vessels. This is indicated by the appearance of a thick line represent-
ing the vena cava and aorta traveling along the midline (Figure 1D,
lines), which is distinct from the thinner central lymphatic vessel and
LNs (Figure 1D, dashed lines). Smaller blood vessels throughout the
body also were labeled and were readily identified in the uninjected
contralateral leg of tumor-bearing mice (Figure 1D, “V”). These find-
ings indicate that the footpad melanoma greatly increases lymph flow
from the tumor through into the blood circulation.
Although our initial analysis using near infrared optical imaging
only revealed increased lymph flow within the tumor-draining pop-
liteal LN [8], high-resolution MRI suggests major enhancement of
lymph drainage that can be detected from the foot tumor through
draining LNs, and extending all the way into the bloodstream. This
finding was confirmed by simultaneous injection of Gadolinium into
both rear toes of tumor-bearing mice, which demonstrated that
lymph drainage is selectively increased in the tumor-draining leg
(Figure 1E ). Thus, the melanoma exerts long-distance effects on
lymph drainage from the footpad tumor through the draining LN
and on into the circulation, without affecting the lymph drainage
of the normal contralateral leg.
Comparison of Contrast-Enhanced Lymphography
and Angiography
The Gd-DTPA contrast has low molecular weight, so that it could
potentially enter the blood circulation directly in addition to travel-
ing through the lymphatics. We used several approaches to determine
whether the labeled vessels are lymphatic or vascular and to assess the
contribution of vascular uptake to the contrast enhancement ob-
served. First, Gd-DTPA injection into the dorsal toe of both feet
of a tumor-bearing mouse demonstrated two central lymphatic ves-
sels (Figure 1E , arrowheads), whereas injection of one leg labeled only
one central lymphatic vessel (Figure 1B, dashed line), as would be
predicted for specific labeling of the paired lymphatic vessels traveling
up the midline. These narrow central lymphatic vessels (Figure 1D,
dashed lines) are distinct from the lightly labeled and wider aorta and
vena cava (Figure 1D, bars). The lymphatic vessel pattern identified by
toe subcutaneous injection (Figure 1B) is also distinct from the blood
vessel pattern identified by intravenous tail vein injection, which labels
the vena cava and aorta on the midline and smaller blood vessels
throughout the mouse (Figure 1F ). Thus, low–molecular weight
Gd-DTPA selectively labels lymphatic vessels after subcutaneous injec-
tion, or blood vessels after intravenous injection, provided that the
mice are imaged soon after contrast injection.
Dynamic Imaging of Tumor Lymph Drainage
The kinetics of lymph drainage were examined by taking rapid
scans every minute for the first 10 minutes after Gd-DTPA injec-
tion, to obtain a time course of contrast flow. Dynamic MIP images
from tumor-bearing versus control mice show major differences in
the rate and amount of lymph flow after injection (Figure 2). Within
1 minute after injection, the tumor-bearing mouse showed contrast
labeling up through the draining LNs (Figure 2D), relative to the
precontrast image (Figure 2B). This lymphatic pattern of contrast
in tumor-bearing mice intensified through 9 minutes after injection
when Gd-DTPA then also labeled the heart, vena cava, and blood
vessels of the uninjected contralateral hind leg (Figure 2H ). In the
control mouse, the contrast weakly labeled the draining LNs and
did not appreciably enter the vascular circulation even at 9 minutes
after injection (Figure 2G ). These findings demonstrate that the
tumor greatly increases the rate of lymphatic drainage.
Movies were generated from dynamic scans of the same control
and tumor-bearing mice imaged in Figure 2 and were processed
using the Volocity software to generate a 3D image over time. These
movies confirmed that lymph flows continuously from the injected
foot through draining LNs and on up the midline to the heart in
normal mice (Figure W1). The movie of the tumor-bearing mouse
illustrated increased lymph flow from the foot to draining LNs, and
then up the midline to the heart and blood circulation (Figure W2).
Interestingly, there was no obvious difference in the number, pattern,
or diameter of lymphatic vessels in tumor-bearing or control mice,
although the popliteal LN draining the tumor was four times larger
than normal [8]. The mechanism by which B16-F10 melanomas in-
crease regional lymph drainage remains to be determined.
Quantification of Tumor-Induced Lymph Flow
The tumor-induced lymph flow alterations were further investi-
gated using quantitative analysis to examine the amount and rate
of contrast transport. The NIH ImageJ software was used to per-
form volumetric image analysis of the dynamic scans, compiled
from images taken over the first 8 minutes after contrast injection
of tumor-bearing or control mice. Regions of interest were drawn
over lymphatic and vascular structures in slices from these volumes,
and the contrast signal was measured at each time point. The inte-
grated density was measured by summing pixel values in the postcon-
trast ROIs and subtracting the sum of precontrast pixel values. For
the assessment of popliteal LNs, the fossa was readily identified in
precontrast images, as illustrated by the ROI drawn in Figure 3A.
Three slices were required to include all of the popliteal fossa in nor-
mal mice. However, the popliteal LN is four times larger than nor-
mal in tumor-bearing mice [8] so that the ROI size was doubled, and
the number of slices analyzed were doubled to six slices for tumor-
draining popliteal LNs. The inguinal LN was identified after labeling
with contrast, so that postcontrast images were used to draw an ROI
over the inguinal LN, as illustrated in Figure 3B. The volume of the
tumor-draining inguinal LN was not significantly increased, so that
equally sized ROIs drawn over the inguinal LN were analyzed in four
slices each from tumor-bearing or control mice.
The integrated density values from tumor-draining left popliteal
LNs increased much more rapidly than values from control popliteal
LNs, and this increase was statistically significant from 3 to 8 minutes
after injection (Figure 4A, left panel ). Measurement of contrast signal
from 0 to 4 minutes demonstrated a fourfold increase in the rate of
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enhancement of contrast in the tumor-draining left popliteal LN,
which was also statistically significant (Figure 4A, right panel ).
Lymph flow through the popliteal LN of the uninjected right hind
leg was also measured to determine how much of the popliteal LN
signal is contributed by vascular spread of contrast into the uninjected
leg. The uptake of contrast into the right popliteal LN was very low in
tumor-bearing or control mice, and the rate of enhancement was neg-
ligible in both cases (Figure 4B). These results confirm that subcuta-
neous injection of Gd-DTPA contrast specifically detects lymph flow,
with negligible labeling of LN blood vessels at early time points.
Quantification of contrast enhancement in the left tumor-draining
inguinal LN showed greatly increased lymph flow relative to control
inguinal LNs, and this increase was statistically significant from 1 to
4 minutes after injection (Figure 4C , left panel ). The rate of contrast
enhancement from 0 to 4 minutes was also significantly increased in
tumor-draining inguinal LNs (Figure 4C , right panel ). The tumor-
draining inguinal LN was only slightly enlarged, so that tumor-
induced lymph flow does not require LN enlargement. The inguinal
LN seems to provide the major lymphatic drainage for the mouse
hind leg, because much more contrast signal was detected in the
tumor-draining inguinal LN (Figure 4C , left panel ) than in the pop-
liteal LN (Figure 4A, left panel ).
Tumors Increase Lymph Drainage into the Blood Stream
The growing B16-F10 melanomas seem to not only enhance
lymph flow through draining LNs, but they also increase lymph de-
livery into the vascular circulation. The kinetics of contrast accumu-
lation in the central lymphatic vessel draining the midline, the heart,
and the right iliac blood vessels were measured to assess whether the
rate of entry of lymph contrast into the bloodstream is significantly
increased in tumor-bearing mice. Regions of interest were drawn over
representative regions, and contrast signal was measured in a single
slice. These area-independent measurements were expressed as per-
cent enhancement (sum of postinjection ROI pixel values minus pre-
contrast pixel values, divided by precontrast values, × 100). An ROI
was drawn over a representative slice showing the central lymphatic
vessel below the heart (as illustrated in Figure 3C ). This analysis
demonstrated increased lymph flow through the central lymphatic
Figure 2. Dynamic MRI analysis of tumor-induced lymph flow. Low-resolution MRI before and after injection of Gd-DTPA into the dorsal
toe (arrow) of a control mouse (left column) and a mouse bearing a tumor in the left hind foot (right column, asterisk indicates the
location of tumor). Dynamic images before injection (A, control; B, tumor-bearing) and at 1 (C, control; D, tumor-bearing), 5 (E, control;
F, tumor-bearing), and 9 minutes (G, control; H, tumor bearing) after injection.
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vessels of tumor-bearing mice, which was significantly higher than
normal from 1 to 3 minutes after contrast injection (Figure 5A).
Entry into the vascular system was assessed by measuring percent
enhancement of a representative ROI in a single slice of the heart
(Figure 3D) or right iliac blood vessels (Figure 3E ). Contrast was sig-
nificantly increased in the heart from 2 to 5 minutes after injection
in tumor-bearing mice (Figure 5B). Contrast appearance in the iliac
blood vessels was further delayed, so that it showed significant in-
creases in tumor-bearing mice from 3 to 6 minutes after injection
(Figure 5C ). Thus, tumor-induced lymph drainage not only in-
creases the amount and rate of lymph flow through the lymphatic
system, but also delivers lymph into the bloodstream at an increased
rate, which can be quantified by dynamic MRI and image analysis.
Discussion
A dynamic contrast-enhanced MRI lymphography assay was de-
veloped in mice, which identified extensive alterations in lymph
drainage induced by metastatic melanomas. Tumor growth in the
footpad was associated with increased lymph flow from the rear leg
through a series of draining LNs and resulted in accelerated con-
trast delivery into the heart and vascular circulation. Tumor-induced
lymph drainage involved an increase in both the amount and the rate
of lymph transport. Tumor-derived signals direct this increased flow,
because increased lymph drainage was restricted to the tumor lym-
phatic drainage basin.
The mechanism by which tumors increase lymph flow is not yet
understood. Early-stage B16-F10 melanomas do not induce lym-
phangiogenesis (or angiogenesis) within the ventral footpad tumor
or the dorsal toe where the contrast was injected [8]. Our MRI stud-
ies demonstrated that there was no obvious increase in the number,
size, or pattern of major leg-draining lymphatic vessels. Instead, the
major physical alteration in the tumor-draining leg was the fourfold
enlargement of the tumor-draining popliteal LN [8]. In addition, the
Figure 3. Identification of lymphatic and vascular structures for
contrast measurement. Representative ROIs drawn for measure-
ment of pixel values are outlined on single-slice images and are
identified using arrows. (A) Popliteal fossa in precontrast image.
(B) Inguinal LN iROI in a postcontrast image. (C) Central lymphatic
vessel ROI in a postcontrast image. (D) Heart ROI in a postcontrast
image from intravenously injected mouse. (E) Iliac blood vessel
ROI in a postcontrast image.
Figure 4. Increased amount and rate of lymph flow through tumor-
draining LNs. The integrated density of Gd-DTPA contrast within
ROIs in the tumor-draining left popliteal (A) and inguinal LNs (C)
is increased in tumor-draining LNs (white circles) relative to control
LNs (black circles; *P < .04, **P < .004, N = 7). In contrast, the
integrated density of Gd-DTPA signal in the nondraining right pop-
liteal LN does not significantly increase relative to normal (B). The
rate of enhancement of Gd-DTPA signal (average increase in inte-
grated density per minute) in the first 4 minutes is significantly in-
creased in the tumor-draining left popliteal (A) and inguinal LNs (C)
but not in the right popliteal LN (B). Standard errors are shown.
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lymphatic sinuses within these tumor-draining popliteal LNs in-
creased ninefold [8]. The tumor-draining inguinal LN showed a
more moderate increase in diameter, whereas it also exhibited exten-
sive lymphangiogenesis (data not shown). Thus, the major alterations
associated with tumor-induced lymph flow are lymphangiogenesis
and enlargement of TDLNs, supporting the idea that these LNs have
an active role in tumor-induced lymph flow [7,8]. Lymph node en-
largement or tumor-reactive lymphadenopathy is commonly ob-
served in human cancer patients [22], suggesting that lymph flow
through draining LNs could also increase in human cancer patients.
Further studies will investigate the contribution of LNs to normal
variations in lymph drainage and to tumor-induced lymph flow.
Our findings are consistent with the hypothesis that LN lymphan-
giogenesis and tumor-induced lymph flow actively drive metastasis
into and through draining LNs [7,8]. This MRI study demonstrates
that accelerated lymph flow is sustained throughout the lymphatic
drainage of the tumor, which could not only promote spread of pri-
mary footpad tumors into the popliteal or inguinal TDLN but also
stimulate secondary lymphatic dissemination to the draining iliac
LN, which is sometimes observed in mice bearing popliteal LN me-
tastases (data not shown). Further evidence that LN alterations pro-
mote metastasis comes from the finding that mutations in the p53 or
p19/Arf tumor suppressors selectively drive LN lymphangiogenesis
and dissemination of squamous cell carcinomas to draining LNs
and to the lungs [23]. Lymph node lymphangiogenesis and increased
tumor-draining lymph flow could predict metastatic potential; how-
ever, these changes could alternatively represent a general feature of
cancers in mice. Further investigations will determine the potential of
tumor-induced lymph flow to predict metastatic potential or to iden-
tify cancer in mice or in humans.
Low–molecular weight gadolinium contrast agents were thought
to be unsuitable for lymphography in the mouse due to their rapid
diffusion out of lymphatic vessels, although they have been success-
fully used for lymphography in larger animals [18,24] and in humans
[17,25]. In fact, Gd-DTPA fails to preferentially label lymphatics in
mice imaged at later times after injection [14,26]. However, we
found that Gd-DTPA makes an excellent contrast agent for kinetic
analysis of lymph flow in mice when they are imaged soon after in-
jection. We did not identify significant leakage out of lymphatic ves-
sels during short-term imaging. Moreover, this small-molecule
contrast was specifically taken up by the lymphatic vessels after sub-
cutaneous injection and did not significantly enter the blood circu-
lation until the lymph reached the heart. These findings are in
agreement with reports of selective lymph uptake after subcutaneous
lymphography in human patients [27].
The efficient uptake of low–molecular weight Gd-DTPA into
the lymphatic system is advantageous for labeling and quantitative
analysis of normal lymphatic vessels and LNs immediately after in-
jection, whereas larger nanoparticles label the lymphatic system much
more slowly [14]. This dynamic MRI scanning strategy using low–
molecular weight contrast can be used to quantitate lymph flow from
the peripheral lymphatic vessels on through the blood circulation. The
lymph drainage basins analyzed can be specified depending on the
location of the subcutaneous injection [28], so that analysis of most an-
atomic regions should be feasible by MRI lymphography. Pilot studies
have not identified toxicity after subcutaneous injection of low–
molecular weight gadolinium contrast for 1.5-T MRI in human sub-
jects [16,17]. However, intravenously injected gadolinium contrast
agents have been associated with nephrogenic systemic fibrosis in pa-
tients with impaired renal function, so that these potential complica-
tions should be considered when using gadolinium contrast [29].
Magnetic resonance imaging lymphography identified tumor-
induced lymph flow from the foot into the heart and blood circulation.
This assay may therefore be useful not only for the identification and
mapping of sentinel LNs [17,25] but also for the diagnosis of tumor-
associated changes in lymph flow. Bilateral contrast injection could
allow internally controlled comparison of lymph flow in the control
versus tumor-draining sides of the body, as was performed for some
of the mice in this study. The kinetics of contrast appearance in the
bloodstream could also be used as an indirect measure of lymph drain-
age. Dynamic contrast-enhanced MRI assessment of tumor-induced
lymph flow could complement other MRI strategies being developed
for cancer diagnosis, such as analysis of LN uptake of iron nanoparticles
in macrophages [30] or iron nanoparticle labeling of tumor cells in
mice [31]. Magnetic resonance imaging lymphography may also be use-
ful for the analysis of experimental lymphedema or lymphatic malfor-
mations in mice [32,33]. Thus, the MRI lymphography assay we have
developed should allow detailed anatomic and quantitative assessment
Figure 5. Tumor-induced lymph flow accelerates contrast arrival in
the bloodstream. (A) The percent enhancement of Gd-DTPA over
the central lymphatic vessel is significantly faster in tumor-bearing
mice (white circles) relative to control mice (black circles) at 1 to
3 minutes after injection (*P < .04, N = 7). (B) Contrast enhance-
ment in the heart is significantly increased at 2 to 5 minutes in
tumor-bearing mice compared to control mice. (C) The percent en-
hancement in the right iliac blood vessels is significantly increased
at 3 to 6 minutes in tumor-bearing mice relative to control mice.
Standard errors are shown.
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of lymph transport throughout the lymphatic system, in cancer and
other diseases in mice, with potential for translation to humans.
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Figure W1. Movie of MRI lymphography in normal mouse. Movie of anesthetized normal mouse during a 10-minute period after
Gd-DTPA injection into the dorsal toe of the left hind leg, illustrating slow lymph transport through the lymphatic vessels and LNs to
the heart. The movie was created from dynamic scans of the mouse shown in the left column of Figure 2.
Figure W2. Movie of MRI lymphography in tumor-bearing mouse illustrates the extent of tumor-induced lymph flow. Movie of anesthe-
tized tumor-bearing mouse during a 10-minute period after Gd-DTPA injection into the dorsal toe of the tumor-bearing hind leg. The
movie illustrates rapid lymphatic transport to the heart and then on through the vascular circulation. The movie was created from dy-
namic scans of the mouse shown in the right column of Figure 2.
